Ge Wen1,2, Weihu Wang1, Yujing Zhang1, Shaoqing Niu1, Qiwen Li1, Yexiong Li1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China. 2. Department of Radiation Oncology, the Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.
Abstract
OBJECTIVE: To investigate potential prognostic factors affecting patient outcomes and to evaluate the optimal methods and effects of radiotherapy (RT) in the management of extramedullary plasmacytoma (EMP). METHODS: Data from 55 patients with EMP between November 1999 and August 2015 were collected. The median age was 51 (range, 22-77) years. The median tumor size was 3.5 (range, 1.0-15.0) cm. The median applied dose was 50.0 (range, 30.0-70.0) Gy. Thirty-nine patients (70.9%) presented with disease in the head or neck region. Twelve patients received RT alone, 9 received surgery (S) alone, 3 received chemotherapy (CT) alone, and 3 patients did not receive any treatment. Combination therapies were applied in 28 patients. RESULTS: The median follow-up duration was 56 months. The 5-year local recurrence-free survival (LRFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) rates were 79.8%, 78.6%, 65.2% and 76.0%, respectively. Univariate analysis revealed that RT was a favourable factor for all examined endpoints. Furthermore, head and neck EMPs were associated with superior LRFS, MMFS and PFS. Tumor size <4 cm was associated with superior MMFS, PFS and OS; serum M protein negativity was associated with superior MMFS and PFS; age ≥50 years and local recurrence were associated with poor MMFS. The dose ≥45 Gy group exhibited superior 5-year LRFS, MMFS and PFS rates (94.7%, 94.4%, 90.0%, respectively), while the corresponding values for the dose <45 Gy group were 62.5% (P=0.008), 53.3% (P=0.036) and 41.7% (P<0.001). CONCLUSIONS: Involved-site RT of at least 45 Gy should be considered for EMP. Furthermore, patients with head and neck EMP, tumor size <4 cm, age <50 years and serum M protein negativity had better outcomes.
OBJECTIVE: To investigate potential prognostic factors affecting patient outcomes and to evaluate the optimal methods and effects of radiotherapy (RT) in the management of extramedullary plasmacytoma (EMP). METHODS: Data from 55 patients with EMP between November 1999 and August 2015 were collected. The median age was 51 (range, 22-77) years. The median tumor size was 3.5 (range, 1.0-15.0) cm. The median applied dose was 50.0 (range, 30.0-70.0) Gy. Thirty-nine patients (70.9%) presented with disease in the head or neck region. Twelve patients received RT alone, 9 received surgery (S) alone, 3 received chemotherapy (CT) alone, and 3 patients did not receive any treatment. Combination therapies were applied in 28 patients. RESULTS: The median follow-up duration was 56 months. The 5-year local recurrence-free survival (LRFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) rates were 79.8%, 78.6%, 65.2% and 76.0%, respectively. Univariate analysis revealed that RT was a favourable factor for all examined endpoints. Furthermore, head and neck EMPs were associated with superior LRFS, MMFS and PFS. Tumor size <4 cm was associated with superior MMFS, PFS and OS; serum M protein negativity was associated with superior MMFS and PFS; age ≥50 years and local recurrence were associated with poor MMFS. The dose ≥45 Gy group exhibited superior 5-year LRFS, MMFS and PFS rates (94.7%, 94.4%, 90.0%, respectively), while the corresponding values for the dose <45 Gy group were 62.5% (P=0.008), 53.3% (P=0.036) and 41.7% (P<0.001). CONCLUSIONS: Involved-site RT of at least 45 Gy should be considered for EMP. Furthermore, patients with head and neck EMP, tumor size <4 cm, age <50 years and serum M protein negativity had better outcomes.
Authors: Richard Soutar; Helen Lucraft; Graham Jackson; Anthony Reece; Jenny Bird; Eric Low; Diana Samson Journal: Br J Haematol Date: 2004-03 Impact factor: 6.998
Authors: Paola Finsinger; Sara Grammatico; Marta Chisini; Alfonso Piciocchi; Robin Foà; Maria T Petrucci Journal: Br J Haematol Date: 2015-12-18 Impact factor: 6.998
Authors: Joachim Yahalom; Tim Illidge; Lena Specht; Richard T Hoppe; Ye-Xiong Li; Richard Tsang; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-01 Impact factor: 7.038
Authors: Mahmut Ozsahin; Richard W Tsang; Philip Poortmans; Yazid Belkacémi; Michel Bolla; Fazilet Oner Dinçbas; Christine Landmann; Bernard Castelain; Jeroen Buijsen; Jürgen Curschmann; Sidney P Kadish; Anna Kowalczyk; Yavuz Anacak; Josef Hammer; Tan D Nguyen; Gabriela Studer; Rachel Cooper; Meriç Sengöz; Luciano Scandolaro; Abderrahim Zouhair Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-17 Impact factor: 7.038
Authors: Justin Komisarof; Jodi Lipof; Joseph DiTursi; Amit Chowdhry; Hae Yoon Grace Choung; W Richard Burack; Louis Constine; Frank Passero Journal: Case Rep Hematol Date: 2022-02-21
Authors: Khaled Elsayad; Michael Oertel; Laila König; Sebastian Hüske; Emmanuelle Le Ray; Mohamed A M Meheissen; Amr Abdelaziz Elsaid; Essam Elfaham; Jürgen Debus; Youlia Kirova; Klaus Herfarth; Hans Theodor Eich Journal: Cancers (Basel) Date: 2020-03-13 Impact factor: 6.639